Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>Report>Interim

Interim

  • Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

    19 May 2023

  • Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851

    23 February 2023

  • Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

    27 October 2022

  • Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

    22 August 2022

  • Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851

    29 July 2022

  • Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), org.nr. 556806-8851

    18 February 2022

  • Interim report for third quarter 2021,1 January – 30 September 2021 Kancera AB (publ.), org.nr. 556806-8851

    19 November 2021

  • Interim report for second quarter 2021. 1 January – 30 June 2021 Kancera AB (publ.)

    20 August 2021

  • Interim report for first quarter 2021, 1 January – 31 March 2021

    21 May 2021

  • Interim report for fourth quarter 2020, 1 January – 31 December 2020

    19 February 2021

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2025 Novakand AB. All Rights Reserved. Design by Clavis Communications